A first step in processing mitochondrial precursor tRNA (pre-tRNA) is cleavage of the 5' leader catalyzed by ribonuclease P (RNase P). Human mitochondrial RNase P (mtRNase P) is composed of three protein subunits: mitochondrial RNase P protein (MRPP) 1, 2 and 3. Even though MRPP3 is the metallonuclease subunit responsible for catalysis, cleavage is observed only in the presence of the MRPP1/2 subcomplex. To understand the functional role of MRPP1/2, we reconstituted human mitochondrial RNase P in vitro and performed kinetic and thermodynamic analyses. MRPP1/2 significantly enhances both the catalytic activity and the apparent substrate affinity of mtRNase P. Additionally, pull-down and binding data demonstrate synergy between binding pre-tRNA and formation of a catalytically active MRPP1/2/3 complex. These data suggest that conformational changes in the MRPP1/2-pre-tRNA complex lead to protein-protein or protein-RNA interactions that increase both MRPP3 recognition and cleavage efficiency. This work presents the first kinetic model for human mtRNase P, providing a fundamental framework for the function of † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
MRPP1/2 for recognition and processing of pre-tRNA.
Dysfunction in mitochondria, the powerhouses of cells, is increasingly implicated in human aging, neurodegenerative diseases, cancer, diabetes, and various rare diseases (1) . While the etiology of many of these diseases remains unknown, mitochondrial dysfunction is frequently linked to damage and mutations in the mitochondrial genome. About half of these disease-related point mutations map to mitochondrial tRNA (mt-tRNA) genes (2) (3) (4) (5) . The human mitochondrial genome is transcribed into three polycistronic transcripts, which are first processed by nuclear-encoded mitochondrial RNase P and RNase Z to generate tRNA with matured 5' and 3' ends, respectively. The combined cleavage activity of RNase P and RNase Z on the polycistronic transcripts also releases the interspersed mRNA, ribosomal RNA and long noncoding RNA transcripts that flank the excised mt-tRNA (6, 7) . Therefore, endonuclease processing of the mitochondrial transcript is a critical step in mitochondrial biogenesis (5, 6) .
Understanding the mt-tRNA processing step catalyzed by human mtRNase P can provide valuable insights into important pathways and protein function in the mitochondria.
RNase P is a divalent metal ion dependent endonuclease found in all domains of life and is the only conserved step in the tRNA maturation pathway. RNase P requires magnesium ions to stabilize the structure of pre-tRNA substrates and to catalyze cleavage of the 5' leader from pre-tRNA in vivo (8) . In many organisms, RNase P is a ribonucleoprotein complex with a catalytic RNA subunit and accessory proteins (9, 10) . However, in plant mitochondria, nuclei, and chloroplasts, a protein-only RNase P (PRORP) functions as a single-subunit endonuclease (11, 12) . A homolog of PRORP, MRPP3, in human mitochondria functions in a multi-subunit complex with MRPP1 and MRPP2 (13) . MRPP3 is the catalytic subunit containing the active site for catalyzing pre-tRNA hydrolysis, but the endonuclease activity is dependent on the presence of MRPP1 and MRPP2 (13) . The mechanistic role of each MRPP subunit for substrate recognition and catalysis is poorly understood.
MRPP1, 2, and 3 are required for the proper processing of mitochondrial transcripts in vivo, including transcripts that encode for respiratory chain complexes. Disruption of these processes leads to mitochondrial dysfunction and disease (14) (15) (16) (17) . Recessive MRPP1 mutations destabilize the mutant protein and lead to inadequate processing of mt-tRNA and low levels of assembled respiratory chain complexes (15) . Pathogenic mutations located in MRPP2 lead to a reduction in MRPP1 and MRPP2 protein levels and tRNA processing (18, 19) . Both MRPP1 and MRPP3 partial knockdown experiments result in enrichment of precursor transcripts indicating a reduction in tRNA and RNA processing (6) . The loss of any of the MRPP3, MRPP1 or MRPP2 in Drosophila causes aberrant tRNA processing and lethality (16) while knockout of MRPP3 is embryonically lethal in mice (17) .
Apart from their roles in human mtRNase P, MRPP1, a tRNA methyltransferase, and MRPP2, a hydroxysteroid (17-β) dehydrogenase, function together in a stable complex (MRPP1/2) to catalyze N1-methylation of A or G at position 9 in mt-tRNA (20) . MRPP2 is an NAD-dependent member of the short-chain dehydrogenase/reductase superfamily involved in the oxidation of isoleucine, steroids, and fatty acids (21, 22) . MRPP1 requires MRPP2 for stability and function, but the dehydrogenase activity and NAD binding capability of MRPP2 are dispensable for methyltransferase activity (13, 23) . MRPP2 mutations and knockdown experiments indicate that MRPP2 is required for stable expression of MRPP1 (19) . Furthermore, the enzymatic activities of MRPP1 and MRPP2 have been reported to have little effect on MRPP3 cleavage activity (23) . The MRPP1/2 complex was also shown to enhance the 3' end processing by the RNase Z enzyme ELAC2 for 17 of the 22 encoded mt-tRNAs (24) . Two crystal structures of MRPP3 with significant N-terminal truncations reveal a distorted active site with no bound metal ions leading to the hypothesis that MRPP1/2 may mediate metal binding at the active site by stabilizing an active conformation of MRPP3 (25, 26) . Alternatively, the N-terminal truncations in MRPP3 may cause the low activity, as suggested by the inability of MRPP1/2 to activate the truncated MRPP3 constructs. Thus, MRPP1 and MRPP2 are proposed to play a scaffolding role in mtRNase P that is independent of their primary catalytic functions (26). However, this proposal remains unverified by biochemical investigations into the role that MRPP1/2 plays in the catalytic pathway of mtRNase P.
Here, we report the first kinetic mechanism of human mtRNase P and uncover the role of the MRPP1/2 subcomplex using a bacterial model pre-tRNA substrate. We performed steady-state and transient kinetics, fluorescence anisotropy binding assays, and pull-down experiments to probe the role of the MRPP1/2 subcomplex. Our data demonstrate that MRPP1/2 enhances the catalytic activity of MRPP3 by increasing substrate affinity and cleavage activity. Furthermore, we find that the MRPP1/2/3 ternary complex is stabilized by pre-tRNA. Kinetic data show that a high concentration of MRPP1/2 is required to activate MRPP3 to efficiently cleave pre-tRNA, consistent with results showing that a partial MRPP1 knockdown had a larger effect on RNA transcript levels in cells compared to a similar level of MRPP3 knockdown (6) . Our data support a kinetic model where MRPP1/2 undertakes a conformational selection step upon binding to pre-tRNA. This work provides a mechanistic framework to understand mt-tRNArelated diseases and will guide future work in dissecting the function of this essential multisubunit RNase P.
RESULTS

MRPP1/2 enhances pre-tRNA cleavage catalyzed by MRPP3
To assess the contribution of MRPP1/2 on mtRNase P function, we performed both multipleturnover (MTO) and single-turnover (STO) kinetics experiments. STO measurements provide insight on the kinetic pathway up to the cleavage step, while MTO kinetics extends to include every step including the product dissociation step. In our MTO experiments, we used a previously described B. subtilis fluorescein-labelled pre-tRNA Asp (Fl-pre-tRNA) substrate with a canonical cloverleaf secondary structure and predicted tertiary fold. This Fl-pre-tRNA was used to elucidate the catalytic mechanism of a homolog of MRPP3 from A. thaliana, PRORP1 (27, 28) . We chose this substrate so we can compare the kinetics of MRPP1/2/3 with PRORP1. STO kinetics and MTO activity with only a single time-point have been previously described for human mtRNase P (13, 14, 23, 24, 29) . Here, we present the first detailed MTO kinetic analysis. MRPP1/2/3 catalyzes complete cleavage of Flpre-tRNA ( Figure 1A ) and the initial rate for cleavage depends on both pre-tRNA and MRPP1/2 concentrations ( Figures 1B, C) . The apparent KM value (KM,app) for pre-tRNA is reduced by at least 4fold, and the apparent turnover rate (kcat, app) is increased by at least 3-fold when MRPP1/2 concentrations are increased from 150 nM to 1200 nM ( Table 1) . At saturating concentrations of MRPP1/2 the catalytic efficiency of MRPP1/2/3 ((kcat/KM),app = 4 x 10 5 M -1 s -1 , Figure 1F and Table  1 ) is comparable to that of A. thaliana PRORP1 (1 x 10 5 M -1 s -1 ) (27) . In the absence of MRPP1/2, no significant product formation is observed under MTO or STO conditions, even after 20 hours incubation of 10 nM pre-tRNA with 25 μM MRPP3 (data not shown). Based on these data, the value of kcat/KM catalyzed by MRPP3 alone is negligible (estimated to be less than 4 M -1 s -1 , Table 1 ). 1 As a result, the MRPP1/2 subcomplex enhances catalytic efficiency by more than 100,000-fold ( Table 1 ). The K1/2 for activation of MRPP3-catalyzed turnover by MRPP1/2 is 0.4 µM ( Figure  1D ). These results demonstrate that MRPP3 efficiently catalyzes pre-tRNA cleavage in the presence of MRPP1/2 and high concentrations of MRPP1/2 are needed for maximal MTO activity.
To determine if catalysis is the rate-limiting step in MRPP1/2/3 cleavage activity, we measured single turnover (STO) kinetics ( Figure 2) . The timedependence of the STO cleavage was fit to a single exponential decay (Figure 2A ). The observed rate constant (kobs) for cleavage catalyzed by MRPP3 has a hyperbolic dependence on the concentration of MRPP1/2 ( Figure 2B ). Additionally, increasing the MRPP3 concentration both enhances the cleavage rate constant at saturating MRPP1/2 (kmax,app) and decreases the K1/2 for MRPP1/2 (K1/2 MRPP1/2 ) more than 3-fold (from 1.0 to 0.3 µM) ( Figure 2B ), consistent with the formation of a MRPP1/2/3•pre-tRNA complex. The K1/2 for MRPP3 at saturating MRPP1/2 (K1/2 MRPP3 ) is 0.094 ± 0.003 µM ( Figure 2C ). The STO cleavage rate constant at saturating MRPP1/2 and MRPP3 (kmax) is 0.21 ± 0.01 s -1 ( Figure 2C , Figure S3 ), similar to the maximum kcat,app value (kchem) calculated from the MTO kinetics ( Figure 1D , Equation 1), indicating that under MTO conditions the cleavage step (kchem) is likely rate-limiting.
Pre-tRNA substrate enhances formation of MRPP-substrate complex
The MTO and STO kinetic data suggest the formation of a MRPP1/2/3 complex that enhances catalytic function. To further investigate the formation of a MRPP1/2/3 complex, we performed in vitro magnetic capture experiments using nickel (II)-coated magneto-beads ( Figure 3 ). If a stable MRPP1/2/3 complex forms, MRPP3 will elute from the resin along with His6-MRPP1/2. Under near-physiological salt conditions (100 mM NaCl), a MRPP1/2/3 complex was not observed, consistent with previous observations (Supplementary Figure  S1) (13, 29) . Even at high MRPP1/2 and MRPP3 concentrations (2.1 μM), the His6-MRPP1/2/3 complex is not observed, indicating a weak affinity of MRPP3 for His6-MRPP1/2 in the absence of pre-tRNA (Lane 3). Upon addition of pre-tRNA to a reaction containing His6-MRPP1/2 and MRPP3 (in CaCl2 to inhibit cleavage), MRPP3 co-elutes with His6-MRPP1/2 demonstrating the formation of a stable MRPP1/2/3 complex in the presence of pre-tRNA (Lane 6). A control experiment demonstrates that MRPP3 does not elute in the absence of His6-MRPP1/2 when pre-tRNA is present (Lane 12). These data reveal an RNA-mediated MRPP1/2/3•pre-tRNA quaternary complex consistent with a recent report by Oerum et al (29) .
Evidence of synergistic binding between MRPP subunits and pre-tRNA
To evaluate whether MRPP1/2 enhances catalytic activity of RNase P by increasing the pre-tRNA binding affinity of MRPP3, we measured apparent dissociation constants (KD,app) for each of the individual subunits using a previously described fluorescence anisotropy (FA) binding assay (12, 30) . We also measured the binding affinity in CaCl2, which allows MRPP1/2/3 to bind, but not cleave substrate on the time-scale of our experiments (data not shown) (12, 27) . In the presence of MgCl2 or CaCl2, MRPP3-alone weakly binds Fl-pre-tRNA (KD,app = 1800 ± 200 nM in MgCl2 or KD,app = 2300 ± 200 nM CaCl2); this value is 1,000-fold weaker than the affinity of the homologous A. thaliana PRORP1 for the same substrate (KD,app = 1.8 nM in CaCl2, Figure 4 , Table  2 ). MRPP1/2 binds Fl-pre-tRNA more tightly (KD,app = 40 ± 4 nM) in MgCl2 ( Figure 4 , Table 2 ). Under CaCl2 conditions, the affinity of MRPP1/2 for Fl-pre-tRNA decreases by 30-fold (KD,app = 1200 ± 100 nM), Figure 4A , Table 2 ). Importantly, the addition of MRPP1/2 (600 nM) increases the apparent binding affinity of MRPP3 for Fl-pre-tRNA by nearly 300-fold in CaCl2 (KD,app = 7 ± 2 nM, Figure 4B , Table 2 ). No significant change in the FA signal was observed upon addition of MRPP2 alone to Fl-pre-tRNA, consistent with a previous gel shift assay study indicating that MRPP2 does not bind pre-tRNA (23) . These data demonstrate that the subunits in the MRPP1/2/3 complex synergize to enhance the substrate binding affinity to a value similar to that of A. thaliana PRORP1.
MRPP3 recognizes MRPP1/2-pre-tRNA as cosubstrate
MRPP1/2 functions similarly to a co-substrate for mtRNase P catalysis. Therefore, we hypothesized that the kinetic stoichiometry measured in reactions ( Figure 2 ) does not necessary equal to a fixed thermodynamic stoichiometry of MRPP1/2/3 ternary complex. We measured the ratio of MRPP1/2 to MRPP3 in the ternary complex from the activation of the MRPP3 cleavage activity by MRPP1/2 under STO conditions. As described above, both the values of kcat,app (MTO) and kobs (STO) catalyzed by MRPP3 display a hyperbolic dependence on the concentration of MRPP1/2 with K1/2,app MRPP1/2 values in the low µM range ( Figure  1D and Figure 2B ). The maximal STO activity (kmax,app) depends on the concentrations of both MRPP1/2 and MRPP3 ( Figure 2B and 2C). These data are consistent with measurement of apparent binding constants involving multiple steps, rather than a single stoichiometric formation of a MRPP1/2/3 complex. Consistent with our hypothesis, the ratio of MRPP1/2 to MRPP3 needed to obtain maximal STO activity (kmax,app) is variable ( Figure 2B and 2C). These data show that the stoichiometry of MRPP subunits (MRPP1:2:3) to achieve the maximal activity is not a simple 2:4:1 ratio, as commonly concluded in previous reports (13, 14, 18, (24) (25) (26) .
The MRPP1/2 subcomplex does not enhance the apparent metal affinity of MRPP3
A possible role for MRPP1/2, as proposed by recent structural studies of MRPP3 (25, 26) , is to enhance binding of metal ions in the active site. Both reported MRPP3 crystal structures lack large portions of the N-terminal region and appear to be in an inactive conformation with no metal ions bound to the active site (25, 26) . To test whether MRPP1/2 activates MRPP3 catalysis by positioning catalytic metal ions in the active site, we measured activation of cleavage activity of MRPP3 by Mg 2+ (K1/2 Mg ) at multiple concentrations of MRPP1/2 under MTO conditions ( Figure S2 , Equation S1). If MRPP1/2 enhances the affinity of the active site for Mg 2+ , we predict that the value of K1/2 Mg would decrease with increasing MRPP1/2 concentration. However, K1/2 Mg remains unchanged between 150 nM and 500 nM MRPP1/2 (K1/2 Mg = 1.9 ± 0.2 mM and 2.5 ± 0.6 mM, respectively). Thus, our data do not support the hypothesis that the MRPP1/2 subcomplex enhances the affinity of catalytic Mg 2+ ions to MRPP3.
DISCUSSION
Kinetic model for mitochondrial RNase P
We sought to understand the role of MRPP1/2 in human MRPP1/2/3 activity. The simplest model for pre-tRNA cleavage catalyzed by human mtRNase P involves the formation of a tertiary protein complex (MRPP1/2/3), followed by the binding and cleavage of pre-tRNA (Scheme 1). However, the data presented in this work and others (13, 18, 25, 26, 29) show that MRPP3 does not strongly associate with MRPP1/2 under physiological conditions (13) and pre-tRNA binds to both MRPP1/2 and MRPP3 subunits ( Figure 4 , Table 2 ). Furthermore, synergistic binding between MRPP1/2/3 and pre-tRNA is observed ( Table 2) and could possibly be explained by the stabilization of the MRPP1/2/3 complex by pre-tRNA ( Figure  3 ). This minimal model also predicts that MTO activity at saturating pre-tRNA is not dependent on the concentration of MRPP1/2 (kcat,app = kchem, see derivation for Scheme 1 and Equations S2, S3 in the Supplementary Data), but this is not true in our experiments where a hyperbolic dependence is clearly observed ( Figure 1D ).
A kinetic model that aligns with both our MTO and binding measurements is shown in Scheme 2. In this model, pre-tRNA binds to MRPP1/2, MRPP3 or the MRPP1/2/3 complex to form catalytically active MRPP1/2/3•pre-tRNA. The Equations describing kinetic parameters for Scheme 2 explain the hyperbolic dependence on the MRPP1/2 concentration observed for kcat,app and KM,app (Figure 1 ; Scheme 2, Supplementary Equations S5, S6, and S7, respectively). Furthermore, no inhibition of the STO rate constant was observed at high concentrations of either MRPP3 or MRPP1/2 (Figure 2 ), indicating that both MRPP3•pre-tRNA and MRPP1/2•pre-tRNA complexes are productive and on a pathway to form a catalytically active MRPP1/2/3•pre-tRNA complex. Therefore, we propose a mechanism with a closed thermodynamic box shown in Scheme 2.
Our experimental data also allow estimation of values for the equilibrium constants shown in Scheme 2: K1 reflects the measured dissociation constant between pre-tRNA and MRPP1/2 (0.04 μM, Table 2 ); K3 is the measured dissociation constant for pre-tRNA binding to MRPP3 (1.8 μM, Figure 3 and Table 2 ); K4 is approximated by the measured K1/2 for enhancement by MRPP1/2 of either the MTO kcat,app (0.4 ± 0.1 μM) ( Figure 1D ) or the STO kmax,app (0.3 ± 0.2 μM, Figure S4 ); and K6 is estimated from the K1/2 for activation of activity by MRPP3 at saturating MRPP1/2 under STO conditions (0.09 μM, Figure 2C ). The value for K5, which describes the affinity of pre-tRNA for the MRPP1/2/3 tertiary complex, is estimated as ≤0.007 μM based on binding experiments ( Figure  3 , Table 2 ). However the thermodynamic box in Scheme 2 requires that K1K6 = K3K4 = K2K5 (Equation S4), which is not the case based on our data (K3= 1.8 µM and K4 = 0.4 µM, therefore K3K4 is comparable within error to K2K5 = 0.8 ± 0.1 µM 2 , but it is not equal to K1K6 since K1= 0.04 µM and K6 = 0.09 µM).
Since the above calculated thermodynamic box is not balanced, the kinetic mechanism may include additional steps that are not shown in Scheme 2. Therefore, we propose a modified kinetic model that includes one additional step (K7): a conformational change step following MRPP1/2 binding to pre-tRNA (Scheme 3). We propose that K1,app is the apparent binding affinity of pre-tRNA for MRPP1/2 (0.04 μM, Table 2 , Equation 5 and 6) and reflects both the binding and conformational change steps (K1). The values for K1 (~0.04 μM) and K7 (~0.005) were estimated from K1,app using Equation 5 . The value of K7 (~0.005) indicate that this conformational change step is unspontaneous (ΔG>0). There is precedence for unspontaneous conformational change steps utilized by multiple important enzymes for ligand recognition (31,32) and a conformational change step has been observed for B. subtilis RNase P catalysis (33) and in PRORP2 structures (34) . Scheme 3 is also consistent with the results from pull-down and MTO experiments. The estimated binding affinity between MRPP1/2 and MRPP3 (K2) is very weak at ≥103 μM (Equation 6), which could explain why no MRPP1/2/3 complex is observed at 2.1 μM of each MRPP proteins ( Figure  3 ). Although Scheme 3 predicts a hyperbolic dependence of (kcat/KM)app on the concentration of MRPP1/2 (Equation 3), the observed linear dependence of (kcat/KM )app on the concentration of MRPP1/2 ( Figure 1F ) is consistent with an linear approximation that can be derived from Equation 3 where the experimental concentration of MRPP1/2 (low μM) is much lower than K2 (103 μM). In addition, we derived Michaelis-Menten equations for many possible thermodynamic models. All kinetic models that did not contain at least one conformational change step did not fit with all of our data. Therefore, we present Scheme 3 as a simplest model that will fit all experimental data and the requirements of a thermodynamic box (Equation 4, 5 and 6).
In summary, Scheme 3 best fits our experimental data, and both qualitatively and quantitatively illustrates the intricate mechanism employed by MRPP1/2 and MRPP3 in mtRNase P catalysis. We propose that the role of MRPP1/2 is to increase the binding affinity of pre-tRNA either by directly contacting pre-tRNA or by altering the structure of MRPP3 or pre-tRNA in a MRPP1/2/3•pre-tRNA complex. Additionally, MRPP1/2 significantly increases the catalytic activity likely by participating in protein-protein and/or protein-RNA contacts, interacting with pre-tRNA and/or MRPP3.
Interplay of pre-tRNA and the MRPP1/2/3 complex
Our data are consistent with structural studies reporting the MRPP1/2/3-tRNA complex and a distorted MRPP3 active site (25, 26, 29) and provide insights into the kinetics and thermodynamics of these interactions. Pre-tRNA stabilizes the MRPP1/2/3 complex as demonstrated by magnetic capture (Figure 3 ) and binding data (Figure 4 , Table  2 ). Furthermore, pre-tRNA has a greater affinity for the full MRPP1/2/3 complex than the separate subunits (Scheme 3). We speculate that upon binding pre-tRNA, changes in protein conformations may lead to changes in proteinprotein contacts between MRPP1/2 and MRPP3, as previously proposed (26,29); and/or alteration of the pre-tRNA structure which leads to enhanced recognition by the catalytic subunit in MRPP3.
The enhanced catalytic efficiency of MRPP1/2/3 may be due to rearrangements in the MRPP3 active site or the bound pre-tRNA structure. MRPP1/2 may play a role in selecting substrates. Given that mammalian mitochondrial tRNAs exhibit noncanonical features, this may provide an explanation for evolving a multi-protein complex for human mtRNase P (5, 35, 36) .
Roles of MRPP1/2 in mitochondrial pre-tRNA processing
The MRPP1/2 subcomplex has a profound effect on pre-tRNA processing, as shown by a significant decrease in catalytic efficiency (100,000-fold, Table 1 ) and substrate affinity (300-fold, Table 2 ) when levels of MRPP1/2 are reduced. These results corroborate in vivo data where siRNA knockdowns of MRPP1 and MRPP3 show differential effects on pre-tRNA processing (6) . When MRPP1 and MRPP3 are reduced by similar levels, the MRPP1 knockdown results in a 10-fold higher accumulation of some pre-tRNA transcripts compared to the MRPP3 knockdown. These in vivo observations combined with our in vitro kinetic data (Figure 1) highlight the obligate role of MRPP1/2 in human mtRNase P catalysis. MRPP1/2 may facilitate catalysis by altering the contacts between MRPP3 and pre-tRNA, stabilizing a catalytically competent structure (Scheme 3). Future work such as transient kinetic characterizations are needed to dissect this mechanism.
In conclusion, MRPP1/2 plays an essential role in mtRNase P by enhancing the catalytic efficiency and substrate affinity of MRPP3. Our proposed model (Scheme 3) provides a framework for investigating and identifying the detailed steps leading to mtRNase P activity. This finding reveals a mechanism likely underpinning the roles of MRPP1/2 in multiple mt-tRNA processing pathways.
EXPERIMENTAL PROCEDURES
Pre-tRNA preparation
Fluorescein-labeled B. subtilis pre-tRNA Asp (Flpre-tRNA) was prepared as previously described with a 5-nucleotide leader and a discriminator base at the 3' end without the 3' CCA sequence (27) . The template was produced from plasmid DNA containing a T7 promoter region and the B. subtilis pre-tRNA Asp sequence by PCR amplification. The in vitro transcription reaction was performed using the PCR template in the presence of guanosine 5'-monothiophosphate (GMPS) (37, 38) . 5'-GMPS-pre-tRNA Asp was prepared by in vitro transcription in the presence of guanosine 5'-monothiophosphate (GMPS) and labeled by reaction with 5-iodoacetamidofluorescein (5-IAF, Life Technologies) overnight at 37 °C to prepare Fl-pre-tRNA (37, 38) . The RNA was purified using a 10% polyacrylamide/bis (39:1) denaturing gel containing 7 M urea. Unlabeled pre-tRNA was prepared using in vitro transcription without the addition of GMPS. Nucleoside triphosphates (NTPs) and chemicals were purchased from Sigma. Inorganic pyrophosphatase was purchased from Roche Applied Science. GMPS was synthesized from 2', 3' isopropylideneguanosine and thiophosphoryl chloride (39) . Recombinant His6-T7 RNA polymerase was expressed in E. coli and purified by Ni-NTA chromatography (40) . Before each assay, FL-pre-tRNA was unfolded at 95 °C for 2 min in water, and refolded by incubation at 37 °C for 15 min followed by addition of the desired buffer and incubation for another 30 min at 37 °C.
Purification of recombinant human MRPPs
To prepare a plasmid for the co-expression and co-purification of the MRPP1/2 subcomplex to achieve increased yield and stability of recombinant MRPP1, DNA encoding an N-terminal truncation of the MRPP1 gene (TRMT10C) (residues 40-403, Δ39MRPP1) with an N-terminal His6-tag followed by a TEV protease site and the full-length MRPP2 gene (SDR5C1) were cloned into a pCDFDuet-1 (Novagen) co-expression vector as previously described (41) . The plasmid was transformed and expressed in Rosetta (DE3) or Rosetta2 (DE3) E. coli cells. Cells were grown in Terrific Broth or auto-induction media (Novagen) containing 50 mg/L streptomycin and 34 mg/L chloramphenicol. Cells grown in Terrific Broth were grown to an OD600 of 0.6-0.8 at 37 ˚C, and then induced by addition of 660 µM β-D-1-thiogalactopyranoside (IPTG) followed by growth for 16 h at 18˚C. Cells grown in auto-induction media were incubated for 24 h at 37 ˚C. Cells were harvested and lysed using a microfluidizer in buffer A (20 mM Tris-HCl or 50 mM 3-(N-Morpholino)propanesulfonic acid (MOPS) (pH 7.5), 1 mM Tris(2carboxyethyl)phosphine (TCEP), and 10% glycerol) containing 1 M NaCl, 15 mM imidazole and one tablet of Complete EDTA free protease inhibitor cocktail (Roche). Cell lysate was pelleted for 60 min at 30,600 × g at 4 °C. The soluble fraction was then applied to a Ni-Sepharose column preequilibrated with buffer A containing 150 mM NaCl. The column was washed with over 10 column volumes (CV) with buffer A containing 150 mM NaCl followed by 1 M NaCl (in buffer A) wash. Bound proteins were eluted by gradient from 50-500 mM imidazole in buffer A over 10 CV. Fractions containing MRPP1/2 were pooled, His6TEV protease was added, and the reaction was dialyzed against buffer A containing 150 mM NaCl.
The sample was then applied to a second Ni-Sepharose column. The flow-through was collected, concentrated, and dialyzed into 50 mM MOPS (pH 7.5), 300 mM NaCl, and 1 mM TCEP. The sample was loaded onto a Sephacryl-200 gelfiltration column (GE Healthcare) preequilibrated with 50 mM MOPS, 1 mM TCEP, and 300 mM NaCl. Protein was eluted at 1 mL/min and the A280 was monitored. Peak fractions were analyzed by SDS-PAGE. Fractions containing MRPP1 and MRPP2 were pooled. The molecular extinction coefficients (ε280) of the individual subunits are 62,130 M -1 cm -1 and 4,720 M -1 cm -1 for Δ39MRPP1 and MRPP2, respectively. The ratio of MRPP1/2 were determined to be 2:4 for calculation of concentration of MRPP1/2 complex as detailed in (41) .
The MRPP3 gene (KIAA0391) with an Nterminal truncation (residues 46-583, Δ45MRPP3) was cloned into a pETM-11 vector that adds an Nterminal His6-tag as previously described (42). The plasmid was transformed and expressed in Rosetta (DE3) E. coli cells. Cells were grown in LB medium at 37 ˚C to an OD600 of 0.6-0.8, and then induced by addition of 660 µM IPTG followed by growth for 16 h at 18˚C. Cells were lysed using a microfluidizer and centrifuged for 60 min at 30,000 × g at 4 °C. The resulting soluble fraction was then applied to a Ni-Sepharose column (GE Healthcare Life Sciences) preequilibrated in buffer B (50 mM MOPS, pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM MgCl2, 1 mM TCEP) with 15 mM imidazole. Buffer B containing 1 M NaCl was used to elute nucleic acid contaminants. Bound proteins were eluted using an imidazole gradient (50-500 mM) in buffer B over 10 CV. Fractions containing MRPP3 were pooled and TEV protease was added and the sample was dialyzed overnight against Buffer B at 4 °C. The sample was then applied to a second Ni-Sepharose column. The flow-through was collected, concentrated, and dialyzed into 50 mM MOPS (pH 7.5), 1 mM TCEP, 150 mM NaCl, and 10 % glycerol. Full-length MRPP2 was expressed in E. coli and purified in a similar manner to that for Δ45MRPP3 as described in (42). The concentrations of Δ45MRPP3 and MRPP2 were determined by absorbance (Δ45MRPP3, ε280 = 85,830 M -1 cm -1 ; MRPP2, ε280 = 4720 M -1 cm -1 ). PRORP1 was purified as previously described (12) .
Multiple-turnover (MTO) cleavage measurements
MTO assays were performed at limiting concentrations of MRPP3 (25-50 nM) and varied concentrations of MRPP1/2 (150-1200 nM) and Flpre-tRNA substrate (150-5000 nM total pre-tRNA containing 40 nM Fl-pre-tRNA). Reactions were initiated by mixing Fl-pre-tRNA with MRPP proteins at 37 °C in reaction buffer (50 mM MOPS pH 7.8, 100 mM NaCl, 4.5 mM MgCl2 and 1 mM TCEP). Reaction time points were quenched with an equal volume of 8 M urea, 100 mM EDTA pH 8, 0.05% bromophenol blue, and 0.05% xylene cyanol. Quenched reactions were resolved on a 22% PAGE containing 7 M urea, and imaged by a Typhoon scanner (λex = 488 nm, λem = 535 nm) ( Figure 1A ). Gels were analyzed using ImageJ software. Initial velocities were determined by 5-12 time points at the linear rate range ( Figure 1B) .
The apparent kinetic parameters (kcat,app, KM,app, and (kcat/KM)app) were determined from a hyperbolic fit (43) of the dependence of the initial velocities divided by the MRPP3 concentration on the MRPP1/2 concentration. The steady-state kinetic equations were derived for kcat,app was fit to the MRPP1/2 dependence of kcat,app to determine the value of kchem at saturating MRPP1/2 concentration and the value for K4 ( Figure 1D ). Equation 2 was fit to the MRPP1/2 dependence of KM,app to estimate values for K4 and K2K5 ( Figure  1E ). In this analysis, the error in the K2K5 value is large (>100%). The value of KM,app approaches K5 at saturating MRPP1/2 (Equation 2). Equation 3 predicts a linear dependence of (kcat/KM)app on MRPP1/2 under these experimental conditions ([M1/2]<<K2). Thus, the value of the linear slope (Equation 3, Figure 1F ) and the value of kchem (Equation 1) were used to calculate the value of K2K5. (within 2-fold of the value of K2K5 estimated using Equation 2) which is used in subsequent analyses. The values of K1,app and K3 were measured by fluorescence anisotropy (FA) binding assays (see below). The values for K1 and K7 were calculated using K1,app and Equations 5 and 6. 
Equation 8
Magnetic capture assay We applied magnetic capture methods (44) using a His6-MRPP1/2 subcomplex (His6-tagged MRRP1 in complex with tag-less MRPP2) to pulldown MRPP3 in vitro. The Ni-NTA magnetic beads (Qiagen) were pre-equilibrated in binding buffer (50mM HEPES pH 7.8, 100 mM NaCl, 4.5 mM CaCl2, and 1 mM TCEP) before incubation with samples containing 2.1 µM His6-MRPP1/2 subcomplex and 2.1 µM MRPP3 with or without 2.1 µM pre-tRNA. The Ni-NTA magnetic beads were incubated with samples for 35 min at room temperature before the flow-through was collected and the beads were washed with binding buffer twice. The samples were eluted with 100 mM EDTA (pH 7.5), and were then run on a SDS-PAGE gel stained with Coomassie Blue.
Fluorescence anisotropy (FA) binding assay
Binding experiments using 10 nM Fl-pre-tRNA and varying concentrations of proteins were carried out in 50 mM MOPS (pH 7.8), 100 mM NaCl, 1 mM TCEP, and 4.5 mM MgCl2 (physiologically relevant divalent metal ion) or CaCl2 (divalent ion in which cleavage by MRPP1/2/3 is inhibited to measure substrate binding). Proteins and Fl-pre-tRNA were incubated at 37 °C for 2 min and the FA values measured in a 384-well plate using a TECAN plate reader. The FA binding data were converted to fraction bound (Yb) using Equation 9, where A0 is the FA value of unbound Fl-pre-tRNA and Ab is the FA value of fully bound protein-Flpre-tRNA complex. All fraction bound data, with the exception of PRORP1, were fit to a binding isotherm (Equation 10, where [P] is the protein concentration). PRORP1 data were fit to a quadratic equation (Equation 11 where L is the concentration (2 nM) of the Fl-pre-tRNA) because the Fl-pre-tRNA concentration is close to the value of the dissociation constant (KD). Acknowledgements: The authors thank Dr. Jane Jackman (Ohio State University) for the kind gift of a MRPP1 plasmid and discussions. The authors also thank Dr. Agnes Karasik, Andrea Stoddard and Dr. Elaina Zverina for helpful suggestions regarding the manuscript, molecular biology and protein purification strategies.
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Author contributions: X. L. and N. W. designed and carried out most of the experiments, analyzed the results, and wrote the manuscript. A.S. further optimized the MRPP1/2 protein purification. B. P. K., M. J. H., and W. H. L. carried some of the molecular biology and protein purifications and provided feedbacks to the manuscript. M. K. and C. A. F supervised the project, provided funding, and revised the manuscript. 8) was fit to the MRPP3 dependence of kmax,app to determine values for the apparent K1/2 MRPP3 (0.094 ± 0.003 µM) and kmax (0.21 ± 0.001 s -1 ). The K1/2 MRPP3 is approximately the value of K6 by rapid-equilibrium approximation under STO conditions. The reported errors and error bars are the standard error of the mean values obtained from fitting the data of five different MRPP1/2 concentrations in (B). -6) or without the His6-MRPP1/2 complex (Lane 7-12). MRPP3 controls with or without pre-tRNA are in Lanes 7-9 and 10-12, respectively. Samples (Lanes 1, 4, 7, and 10) were loaded onto Ni-NTA magnetic agarose beads and incubated at room temperature for 35 min. The flow-through (FLT) was collected (Lanes 2, 5, 8, and 11). 100 mM EDTA (pH 8) was used to elute the protein and RNA from the beads (Lanes 3, 6, 9, and 12). 9) measuring the binding of 10 nM Fl-pre-tRNA to varied concentrations of MRPP1/2 (inverted triangles), MRPP3 (triangles), MRPP2 (diamonds), and MRPP3 with 150 nM MRPP1/2 (squares). The concentration of Fl-pre-tRNA was reduced to 2 nM for PRORP1 (dots). FA is measured after a 2-5 min incubation. A binding isotherm (Equation 10) was fit to the data except for PRORP1, which was fit to a quadratic equation (Equation 11). Dissociation constants (KD,app) are listed in Table 2 . (B) Apparent affinity of MRPP3 (KD,app,MRPP3) to Fl-pre-tRNA in the presence of MRPP1/2. The FA binding assay was performed using 10 nM Fl-pre-tRNA with varying MRPP3 concentrations at a constant MRPP1/2 concentration (0, 150, or 600 nM). The errors reported are from the fit of the fraction bound curve obtained from FA data (11 to 17 protein concentrations) as shown in (A).
